The Case for an Estrogen-iron Axis in Health and Disease

Abstract

Clinical and experimental evidence suggest that estrogen manipulates intracellular iron metabolism and that elevated levels of estrogen associate with increased systemic iron availability. This has been attributed to the ability of estrogen to suppress hepcidin synthesis, maintain ferroportin integrity and enhance iron release from iron-absorbing duodenal enterocytes and iron-storing macrophages and hepatocytes. These observations speak of a potential “estrogen-iron” axis that manipulates iron metabolism in response to hematologic (erythropoiesis) and non-hematologic (uterine growth, pregnancy, lactation) needs for iron. Such an axis could contribute to minimizing iron deficiency in premenopausal women and iron overload in postmenopausal women. It could also exacerbate iron overload and related clinical consequences including cancer, osteoporosis, cardiovascular complications and neurodegenerative symptoms, especially in postmenopausal women on hormonal replacement therapy. Understanding the role of estrogen in iron metabolism may shed some light on the pleotropic, but often paradoxical, roles of estrogen in human health and disease.

Key words

hepcidin - ferritin - ferroportin - hormonal replacement therapy - iron - menopause

• References

• 1 Cui J, Yong S, Li R. Estrogen synthesis and signaling pathways during ageing: From periphery to brain. Trends Mol Med 2013; 19: 197-209
• 2 Prossnitz ER, Arterburn JB, Sklar LA. GPR30: A G protein-coupled receptor for estrogen. Mol Cell Endocrinol 2007; 265-266: 138-142
• 3 Marin R, Diaz M. Estrogen interactions with lipid rafts related to neuroprotection. Impact of brain ageing and menopause. Front Neurosci 2018;
• 4 Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19: 833-842
• 5 Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annual Reviews of Medicine 2011; 62: 347-360
• 6 Anderson GJ, Wang F. Essential but toxic: Controlling the flux of iron in the body. Clin Exp Pharmacol Physiol 2012; 39: 719-724
• 7 Nemeth E, Tuttle MS, Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
• 8 Peyssonnaux C, Zinkernagel AS, Schuepbach RA. et al. Regulation of iron homeostasis by the hypoxia-inducible transcription factors [HIFs]. J Clin Invest 2007; 117: 1926-1932
• 9 Tanno T, Bhanu NV, Oneal PA. et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 3: 1096-1101
• 10 Silvestri L, Pagani A, Nai A. et al. The serine protease matriptase-2 [TMPRSS6] inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008; 8: 502-511
• 11 Schmidt PJ, Toran PT, Giannetti AM. et al. The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. Cell Metab 2008; 7: 205-214
• 12 Lee P, Peng H, Gelbart T. et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. PNAS 2005; 102: 1906-1910
• 13 Nemeth E, Rivera S, Gabayan V. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone. J Clin Invest 2004; 113: 1271-1276
• 14 Meynard D, Kautz L, Darnaud V. et al. Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 2009; 41: 478-481
• 15 Andriopoulos Jr B, Corradini E, Xia Y. et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482-487
• 16 Wang RH, Li C, Xu X. et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab 2005; 2: 399-409
• 17 Raso GM, Irace C, Esposito E. et al. Ovariectomy and estrogen treatment modulate iron metabolism in rat adipose tissue. Biochem Pharmacol 2009; 78: 1001-1007
• 18 Horiguchi H, Oguma E, Kayama F. The effects of iron deficiency on estradiol-induced suppression of erythropoietin induction in rats: Implications of pregnancy-related anemia. Blood 2005; 106: 67-74
• 19 Pentecost BT, Teng CT. Lactotransferrin is the major estrogen inducible protein of mouse uterine secretions. J Biol Chem 1987; 262: 10134-10139
• 20 Stuckey R, Aldridge T, Lima FL. et al. Induction of iron homeostasis genes during estrogen-induced uterine growth and differentiation. Mol Cell Endocrinol 2006; 253: 22-29
• 21 Harrison-Findik DD. Gender-related variations in iron metabolism and liver diseases. World J Hepatol 2010; 2: 302-310
• 22 Qian Y, Zhang S, Guo W. et al. Polychlorinated Biphenyls (PCBs) Inhibit hepcidin expression through an estrogen-like effect associated with disordered systemic iron homeostasis. Chem Res Toxicol 2015; 28: 629-640
• 23 Bajbouj K, Shafarin J, Allam H. et al. Elevated levels of estrogen suppress hepcidin synthesis and enhance serum iron availability in premenopausal women. Exp Clin Endocrinol Diabetes 2018;
• 24 Ulas M, Cay M. Effects of 17b-estradiol and vitamin E treatments on blood trace element and antioxidant enzyme levels in ovariectomized rats. Biol Trace Elem Res 2011; 139: 347-355
• 25 Huang X, Xu Y, Partridge NC. Dancing with sex hormones, could iron contribute to the gender difference in osteoporosis?. Bone 2013; 55: 458-460
• 26 Akinloye O, Adebayo TO, Oguntibeju OO. et al. Effects of contraceptives on serum trace elements, calcium and phosphorus levels. West Indian Med J 2011; 60: 308-315
• 27 Milman N, Kirchhoff M, Jørgensen T. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 1992; 65: 96-102
• 28 Lehtihet M, Bonde Y, Beckman L. et al. Circulating Hepcidin-25 is reduced by endogenous estrogen in humans. PLoS ONE 2016; 11: e0148802
• 29 Bajbouj K, Shafarin J, Abdalla MY. et al. Estrogen-induced disruption of intracellular iron metabolism leads to oxidative stress, membrane damage, and cell cycle arrest in MCF-7 cells. Tumour Biol 2017; 39: 1010428317726184
• 30 Shafarin J, Bajbouj K, El-Serafy A. et al. Estrogen-dependent downregulation of hepcidin synthesis induces intracellular iron efflux in cancer cells in vitro. Biology and Medicine 2016; 8: 356. doi:10.4172/0974-8369.1000356
• 31 Yang Q, Jian J, Katz S. et al. 17β-estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinol 2012; 153: 3170-3178
• 32 Hou Y, Zhang S, Wang L. et al. Estrogen regulates iron homeostasis through governing hepatic hepcidin expression via an estrogen response element. Genetics 2012; 11: 398-403
• 33 Hua K, Din J, Cao Q. et al. Estrogen and progestin regulate HIF-1alpha expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. Oncol Rep 2009; 21: 893-898
• 34 Kazi AA, Molitoris KH, Koos RD. Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus. Biol Reprod 2009; 81: 378-378
• 35 Ikeda Y, Tajima S, Izawa-Ishizawa Y. et al. Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes. PLoS ONE 2012; 7: e40465
• 36 Zhen AW, Nguyen NH, Gibert Y. et al. The small molecule, genistein, increases hepcidin expression in human hepatocytes. Hepatology 2013; 58: 1315-1325
• 37 Scott DE. Anemia in pregnancy. Obstetrics & Gynecology Annual 1972; 1: 219-244
• 38 Bothwell TH. Iron requirements in pregnancy and strategies to meet them. Am J Clin Nutr 2000; 72: 257S-264S
• 39 Gao G, Liu SY, Wang HJ. et al. Effects of Pregnancy and Lactation on Iron Metabolism in Rats. Biomed Res Int 2015; ID 105325
• 40 Millard KN, Frazer DM, Wilkins SJ. et al. Changes in the expression of intestinal iron transport and hepatic regulatory molecules explain the enhanced iron absorption associated with pregnancy in the rat. Gut 2004; 53: 655-660
• 41 Koenig MD, Tussing-Humphreys L, Day J. et al. Hepcidin and Iron Homeostasis during Pregnancy. Nutrients 2014; 6: 3062-3083
• 42 Buster JE, Carson SA. Placental endocrinology and diagnosis of pregnancy. In Gabbe SG, Niebyl JR, Simpson JL. eds Obstetrics: Normal and Problem Pregnancies. 2^nd ed New York: Churchill Livingstone; 1991: 59-91
• 43 Nakada D, Oguro H, Levi BP. et al. Estrogen increases haematopoietic stem cell self-renewal in females and during pregnancy. Nature 2014; 505: 555-558
• 44 Bothwell TH, Charlton RW. A general approach of the problems of iron deficiency and iron overload in the population at large. Semin Hematol 1982; 19: 54-67
• 45 Fairbanks VF. Iron in medicine and nutrition. In Shils ME, Shike M, Ross AC. et al. eds Modern Nutrition in Health and Disease. 10th ed Baltimore: Lippincott Williams & Wilkins; 1999: 193-221
• 46 Zittermann A, Schwarz I, Scheld K. et al. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women A. J Clin Endocrinol Metab 2000; 85: 95-101
• 47 Finch CA, Bellotti V, Stray S. et al. Plasma ferritin determination as a diagnostic tool. West Journal of Medicine 1986; 145: 657-663
• 48 Jian J, Pelle E, Huang X. Iron and menopause: does increased iron affect the health of postmenopausal women?. Antioxid Redox Signal 2009; 11: 2939-2943
• 49 Liu JM, Hankinson SE, Stampfer MJ. et al. Body iron stores and their determinants in healthy postmenopausal US women. Am J Clin Nutr 2003; 78: 1160-1167
• 50 Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now?. Lancet 2005; 366: 409-421
• 51 Murday HK, Rusli FD, Blandy C. et al. Night sweats: it may be hemochromatosis. Climacteric 2016; 19: 406-408
• 52 Kim BJ, Ahn SH, Bae SJ. et al. Iron overload accelerates bone loss in healthy postmenopausal women and middle-aged men: A 3-year retrospective longitudinal study. JBMR 2012; 27: 2279-2290
• 53 Cho GJ, Shin JH, Yi KW. et al. Serum ferritin levels are associated with metabolic syndrome in postmenopausal women but not in premenopausal women. Menopause 2011; 18: 1120-1124
• 54 Sukumaran A, Chang JO, Han M. et al. Iron overload exacerbates age-associated cardiac hypertrophy in a mouse model of hemochromatosis. Sci Rep 2017; 7: 5756
• 55 Harvey RE, Coffman KE, Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Women’s Health [Lond] 2015; 11: 239-257
• 56 Dye RV, Miller KJ, Singer EJ. et al. Hormone replacement therapy and risk for neurodegenerative diseases. J Alzheimers Dis Rep 2012; 258454
• 57 Brigham D, Beard J. Iron and thermoregulation: A review. Crit Rev Food Sci Nutr 1996; 36: 747-763
• 58 Zacharski LR, Ornstein DL, Woloshin S. et al. Association of age, sex, and race with body iron stores in adults: Analysis of NHANES III data. Am Heart J 2000; 140: 98-104
• 59 Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and Cancer Risk – A Systematic Review and Meta-analysis of the Epidemiological Evidence. Cancer Epidemiol Biomarkers Prev 2014; 23: 12-32
• 60 Pinnix ZK, Miller LD, Wang W. et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010; 2: 43ra56
• 61 Shpyleva SI, Tryndyak VP, Kovalchuk O. et al. Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat 2011; 126: 63-71
• 62 Yang J, Bielenberg DR, Rodig SJ. et al. Lipocalin 2 promotes breast cancer progression. PNAS 2009; 106: 3913-3918
• 63 Yang J, McNeish B, Butterfield C. et al. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB Journal 2013; 27: 45-50
• 64 Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 27082
• 65 Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997; 57: 3071-3078
• 66 Jordan VC. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: The origins of targeted therapy and chemoprevention. Cancer Res 2009; 69: 1243-1254
• 67 Wang K, Li F, Chen L. et al. Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies. Oncotarget 2017; 8: 81109-81124
• 68 Kim S, Ko Y, Lee HJ. et al. Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies. Breast Cancer Res Treat 2018;
• 69 Bajbouj K, Shafarin J, Hamad M. High-Dose Deferoxamine Treatment Disrupts Intracellular Iron Homeostasis, Reduces Growth, and Induces Apoptosis in Metastatic and Nonmetastatic Breast Cancer Cell Lines. Technol Cancer Res Treat 2018; 17: 1533033818764470
• 70 Haddow A, Watkinson JM, Paterson E. et al. Influence of synthetic oestrogens on advanced malignant disease. Br Med J 1944; 2: 393-398
• 71 Ingle JN, Ahmann DL, Green SJ. et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981; 304: 16-21
• 72 Peethambaram PP, Ingle JN, Suman VJ. et al. Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999; 54: 117-122
• 73 Jordan VC. The 38th David A. Karnofsky Lecture: The paradoxical actions of estrogen in breast cancer—survival or death?. J Clin Oncol 2008; 26: 3073-3082
• 74 Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991; 265: 1861-1867
• 75 Grady D, Rubin SM, Petitti DB. et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037
• 76 Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72
• 77 Hulley S, Grady D, Bush T. et al. Heart and Estrogen/progestin Replacement Study [HERS] Research Group Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA 1998; 280: 605-613
• 78 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women’s Health Initiative randomized controlled trial. Writing Group for the Women’s Health Initiative Investigators. JAMA 2002; 288: 321-333
• 79 Tuomainen TP, Punnonen K, Nyyssönen K. et al. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998; 97: 1461-1466
• 80 Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792
• 81 Meroño T, Gómez L, Sorroche P. et al. High risk of cardiovascular disease in iron overload patients. Eur J Clin Invest 2011; 41: 479-486
• 82 Basuli D, Stevens RG, Torti FM. et al. Epidemiological associations between iron and cardiovascular disease and diabetes. Front Pharmacol 2014; 5: 117. doi:10.3389/fphar.2014.00117
• 83 van der A DL, Grobbee DE, Roest M. et al. Serum ferritin is a risk factor for stroke in postmenopausal women. Stroke 2005; 36: 1637-1641
• 84 Jamshed N, Ozair FF, Aggarwal P. et al. Alzheimer disease in post-menopausal women: Intervene in the critical window period. J Medwife Health 2014; 5: 38-40
• 85 Imtiaz B, Tuppurainen M, Rikkonen T. et al. Postmenopausal hormone therapy and Alzheimer disease: A prospective cohort study. Neurology 2017; 88: 1062-1068
• 86 Petitti D, Buckwalter JG, Crooks VC. et al. Prevalence of dementia in users of hormone replacement therapy as defined by prescription data. J. Gerontol A [Biological Sciences and Medical Sciences] 2002; 57: M532-M538
• 87 Lei P, Ayton S, Finkelstein DI. et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012; 18: 291-295
• 88 Popat RA, Van Den Eeden SK, Tanner CM. et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005; 65: 383-390
• 89 Guggenbuhl P, Deugnier Y, Boisdet JF. et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int 2005; 16: 1809-1814
• 90 Valenti L, Varenna M, Fracanzani AL. et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 2009; 20: 549-555
• 91 Valenti L, Varenna M, Fracanzani AL. et al. Association between iron overload and osteoporosis in patients with hereditary hemochromatosis. Osteoporos Int 2009; 20: 549-555
• 92 Doyard M, Chappard D, Leroyer P. et al. Decreased Bone Formation Explains Osteoporosis in a Genetic Mouse Model of Hemochromatosiss. PLoS ONE 2016; 11: e0148292
• 93 Yamasaki K, Hagiwara H. Excess iron inhibits osteoblast metabolism. Toxicol. Lett 2009; 191: 211-215
• 94 Yang Q, Jian J, Abramson SB. et al. Inhibitory effects of iron on bone morphogenetic protein 2-induced steoblastogenesis. J Bone Miner Res 2011; 26: 1188-1196
• 95 Ishii KA, Fumoto T, Iwai K. et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009; 15: 259-266
• 96 Tsay J, Yang Z, Ross FP. et al. Bone loss caused by iron overload in a murine model: Importance of oxidative stress. Blood 2010; 116: 2582-2589
• 97 Zarjou A, Jeney V, Arosio P. et al. Ferritin ferroxidase activity: A potent inhibitor of osteogenesis. J Bone Miner Res 2010; 25: 164-172
• 98 Nelson HD. Hormone Replacement Therapy and Osteoporosis. Rockville [MD], Agency for Healthcare Research and Quality [US], Preventive Services Task Force Evidence Syntheses 2002 [accessed May 4th, 2018]
• 99 The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions [PEPI] trial. JAMA 1996; 276: 1389-1396
• 100 Ten Bolscher M, Netelenbos JC, Barto R. et al. Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat. J Bone Miner Res 1999; 14: 1197-1202
• 101 Prince RL, Dick I. Oestrogen effects on calcium membrane transport: A new view of the inter-relationship between oestrogen deficiency and age-related osteoporosis. Osteoporos Intl 1997; 7 [Supplement 3] SlSG-S1S4
• 102 Prince RL, Smith M, Dick IM. et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. NEJM 1991; 325: 1189-1195
• 103 Reid IR, Ames RW, Evans MC. et al. Effect of calcium supplementation on bone loss in postmenopausal women. NEJM 1993; 328: 460-464
• 104 Yin X, Wang X, Hu X. et al. ERβ induces the differentiation of cultured osteoblasts by both Wnt/β-catenin signaling pathway and estrogen signaling pathways. Exp Cell Res 2015; 5: 107-114
• 105 Qiu X, Jin X, Shao Z. et al. 17β estradiol induces the proliferation of hematopoietic stem cells by promoting the osteogenic differentiation of mesenchymal stem cells. Tohoku J Exp Med 2014; 233: 141-148
• 106 Mishra S, Tai Q, Gu X. et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. Oncotarget 2015; 6: 44388-44402
• 107 Song L, Zhao J, Zhang X. et al. Icariin induces osteoblast proliferation, differentiation and mineralization through estrogen receptor-mediated ERK and JNK signal activation. Eur J Pharmacol 2013; 714 [1-3] 15-22